F-star Therapeutics, Inc.
If you purchased F-star Therapeutics, Inc. securities and would like to join the action, please click "Join This Action" below.
FSTX STOCK ALERT: HALPER SADEH LLP IS INVESTIGATING WHETHER THE SALE OF F-STAR THERAPEUTICS, INC. IS FAIR TO SHAREHOLDERS
June 23, 2022.
New York, New York—Halper Sadeh LLP, an investor rights law firm, is investigating whether the sale of F-star Therapeutics, Inc. (NASDAQ: FSTX) to invoX Pharma for $7.12 per share is fair to F-star shareholders.
The investigation concerns whether F-star and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for F-star shareholders; (2) determine whether invoX is underpaying for F-star; and (3) disclose all material information necessary for F-star shareholders to adequately assess and value the merger consideration. On behalf of F-star shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.